Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 23, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 23, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg.".